Last reviewed · How we verify

Tazarotene 0.1% gel

Galderma R&D · FDA-approved active Small molecule

Tazarotene 0.1% gel is a Retinoid Small molecule drug developed by Galderma R&D. It is currently FDA-approved for Acne vulgaris, Plaque psoriasis, Photoaging and facial wrinkles. Also known as: Tazret gel 0.1%, TAZORAC® Gel 0.1%, TAZORAC® Cream 0.1%, Tazarotene.

Tazarotene is a retinoid that binds to retinoid X receptors (RXR) and retinoid acid receptors (RAR) to regulate gene expression and promote skin cell differentiation and turnover.

Tazarotene is a retinoid that binds to retinoid X receptors (RXR) and retinoid acid receptors (RAR) to regulate gene expression and promote skin cell differentiation and turnover. Used for Acne vulgaris, Plaque psoriasis, Photoaging and facial wrinkles.

At a glance

Generic nameTazarotene 0.1% gel
Also known asTazret gel 0.1%, TAZORAC® Gel 0.1%, TAZORAC® Cream 0.1%, Tazarotene, tazarac
SponsorGalderma R&D
Drug classRetinoid
TargetRetinoid X receptor (RXR), Retinoid acid receptor (RAR)
ModalitySmall molecule
Therapeutic areaDermatology
PhaseFDA-approved

Mechanism of action

As a third-generation retinoid, tazarotene selectively activates RXR and RAR nuclear receptors, which modulate transcription of genes involved in cell proliferation, differentiation, and inflammation. This leads to normalization of keratinization, reduced sebum production, and anti-inflammatory effects in the skin. The mechanism makes it effective for treating acne and psoriasis by promoting epidermal cell turnover and reducing comedone formation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tazarotene 0.1% gel

What is Tazarotene 0.1% gel?

Tazarotene 0.1% gel is a Retinoid drug developed by Galderma R&D, indicated for Acne vulgaris, Plaque psoriasis, Photoaging and facial wrinkles.

How does Tazarotene 0.1% gel work?

Tazarotene is a retinoid that binds to retinoid X receptors (RXR) and retinoid acid receptors (RAR) to regulate gene expression and promote skin cell differentiation and turnover.

What is Tazarotene 0.1% gel used for?

Tazarotene 0.1% gel is indicated for Acne vulgaris, Plaque psoriasis, Photoaging and facial wrinkles.

Who makes Tazarotene 0.1% gel?

Tazarotene 0.1% gel is developed and marketed by Galderma R&D (see full Galderma R&D pipeline at /company/galderma-r-d).

Is Tazarotene 0.1% gel also known as anything else?

Tazarotene 0.1% gel is also known as Tazret gel 0.1%, TAZORAC® Gel 0.1%, TAZORAC® Cream 0.1%, Tazarotene, tazarac.

What drug class is Tazarotene 0.1% gel in?

Tazarotene 0.1% gel belongs to the Retinoid class. See all Retinoid drugs at /class/retinoid.

What development phase is Tazarotene 0.1% gel in?

Tazarotene 0.1% gel is FDA-approved (marketed).

What are the side effects of Tazarotene 0.1% gel?

Common side effects of Tazarotene 0.1% gel include Skin irritation (erythema, peeling, dryness), Photosensitivity, Burning or stinging sensation, Pruritus.

What does Tazarotene 0.1% gel target?

Tazarotene 0.1% gel targets Retinoid X receptor (RXR), Retinoid acid receptor (RAR) and is a Retinoid.

Related